Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus VERMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus VERMIDOL.
EMVERM vs VERMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
VERMIDOL is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and attenuating pain, inflammation, and fever.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
200 mg orally twice daily for 3 days; maximum 400 mg per day.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Terminal elimination half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h) and elderly.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Renal: ~60-70% as unchanged drug; biliary/fecal: ~20-30%; minor metabolism via hepatic CYP3A4.
Category C
Category C
Anthelmintic
Anthelmintic